Whoopi Goldberg Warns Against AI-Created Ad Using Her Image to Sell Weight-Loss Drug: ‘Do Not Fall for It!’
The EGOT winner railed against an ad that's circulating on social media with a manipulated version of her promoting "bad ...
Whoopi Goldberg addresses 'phony weight loss ad' depicting her on Instagram
"The View" co-host Whoopi Goldberg addressed a "phony weight loss ad" circulating on Instagram during the show on Wednesday ...
Sharon Osbourne emerges for the first time in months as she announces Black Sabbath reunion - after admitting she's still suffering Ozempic side effects despite q…
Sharon was on hand to promote the event alongside the band's originals guitarist Tony Iommi, after admitting she is ...
‘The View’s Whoopi Goldberg Blasts “Phony” AI Weight Loss Ad Using Her Face: “It’s A Lot Of BS, Do Not Fall For It”
Whoopi Goldberg took to The View to blast a "phony" AI weight loss ad running on social media that is using her image to ...
Whoopi Goldberg issues warning about fake social media ad of her endorsing weight loss treatment
Whoopi Goldberg has warned fans about a fake advertisement, which features an AI-edited video of her endorsing a weight loss ...
BioPharma Dive2h
Novo outlines new late-stage study of obesity drug CagriSema
CagriSema, which underperformed expectations in its first Phase 3 test, will be studied at different doses and for longer ...
My encounter from hell with Lottie Moss: MOLLY CLAYTON reveals how she was left stunned by Kate's 'rude' half-sister - as the retired OnlyFans star turns her attention …
As Lottie Moss appears on Celebrity Bear Hunt, MOLLY CLAYTON describes the moment she met the younger sister of supermodel ...
Novo Nordisk defends next-gen obesity drug CagriSema, details new trial
Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...
Novo Nordisk: Among The Best Opportunities Of The Moment (Rating Upgrade)
Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential. Click to read why NVO is a Strong Buy.
Study warns diabetic 'yo-yo' dieting can hurt kidneys in those with type 1 diabetes
"Yo-yo" dieting --- repeatedly losing and gaining weight -- can significantly increase risk of kidney disease among people ...
STAT5h
Pharmalittle: We’re reading about an FDA hold on an Amgen obesity drug, imported Canadian drugs, and more
The U.S. Food and Drug Administration ordered a hold on a study of an early-stage obesity drug being developed by Amgen, another potential setback in the company’s efforts to join the booming weight ...
Novo Nordisk defends next-gen obesity drug CagriSema, gives details of new trial
Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...